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Since multiple daily pre-meal short-acting insulin injections can de-
crease postprandial glycemic excursions, it would be a promising
strategy for preventing vascular injury in diabetes. However, which
type of short-acting insulin therapy is best for reducing sRAGE levels
and improving patient satisfaction remains unclear. To address
the issue, we compared clinical effects of glulisine-based bolus insulin
therapy with those of other short-acting insulin in type 2 diabetic
patients.
This was a prospective, open-label, 24-week study. 26 consecutive
type 2 diabetic outpatients seen in the clinic of Sapporo City General
Hospital whose blood glucose levels were uncontrolled (HbA1c N6.2%)
by pre-meal injections of bolus short-acting insulin (aspart (n = 9),The pathological role of the non-enzymatic modiﬁcation of proteins
by reducing sugars, a process that is known as glycation (also called
the “Maillard reaction”), has become increasingly evident in various
types of diseases [1–5]. The early glycation products undergo pro-
gressive modiﬁcation over time in vivo to the formation of irrevers-
ibly cross-linked, heterogeneous ﬂuorescent derivatives termed
“advanced glycation end products (AGEs)” [1–5]. There is accumu-
lating evidence that activation of the receptor for AGEs (RAGE)
evokes oxidative and inﬂammatory reactions, thereby contributing
to vascular complications in diabetes [2–5]. Further, recently, soluble
form of RAGE (sRAGE) has been indentiﬁed and could reﬂect tissue
RAGE expression in diabetes [6]. Moreover, prospective studies have
shown that higher levels of sRAGE are associated with incident of
cardiovascular disease or all-cause mortality in diabetic subjects [6,7].
These ﬁndings suggest that sRAGE might be a biomarker of cardio-
vascular disease in diabetes and a potential therapeutic target for
intervention.
Postprandial hyperglycemia is of greater importance in cardio-
vascular disease in patients with impaired glucose tolerance or dia-
betes [8]. It is associated with endothelial dysfunction and increasedysiology and Therapeutics of
chool of Medicine, 67 Asahi-
gishi).
.lispro (n = 13) and regular human insulin (n = 1)) for at least
8 weeks were enrolled in this study. All patients were assigned to
replace short-acting insulin by glulisine. Some part of subjects was en-
rolled in our previous glargine plus glulisine study [9]. Doses of glulisine
were titrated to reach and maintain target glycemic goals deﬁned as
postprandial glucose levels of 160 mg/dL or lower. During the study pe-
riod, subjects were instructed not to change their lifestyles and to con-
tinue taking the same dose of any concomitant oral drugs.We excluded
any patients with inﬂammatory, neoplastic disorders, or those who
had a recent (b3 months) cardiovascular disease. Three patients
dropped out of the study during the assessment due to colon cancer,
stroke and poor adherence to treatment. Finally 23 patients were eval-
uated at baseline and 24 weeks of follow-up. All participants gave in-
formed consent to participate in this study. The Ethical Committee for
the Clinical Research of Sapporo City General Hospital approved this
study.
Blood pressure (BP)wasmeasured in the sitting position using an up-
right standard sphygmomanometer. Blood was drawn after 12-hour
fasting in the morning, and blood chemistries, including sRAGE and
monocyte chemoattractant protein-1 (MCP-1), were measured as de-
scribed previously [9]. Urinary albumin excretion (UAE) levels weremea-
sured by immunoturbidimetry assay (Hitachi LABOSPECT 008, Tokyo,
Japan). Patient satisfaction was assessed with Diabetes Treatment Satis-
faction Questionnaire (DTSQ) [10]. DTSQ score assesses total diabetes
treatment satisfaction with higher scores indicating higher satisfaction.
Perceived frequency of hyperglycemia and hypoglycemia is also
Table 1
Clinical characteristics.
Parameters Baseline 24 weeks after
replacement
p-Value
Number 23 23 –
Male/female (number) 12/11 12/11 –
Age (years old) 59.4 ± 12.3 – –
Duration of diabetes (years) 19.0 ± 8.3 – –
Retinopathy/nephropathy
(number)
14/10 14/10 –
Body weight (kg) 69.3 ± 14.0 70.0 ± 14.5 0.063
Plasma glucose (mg/dL) 172.0 ± 92.8 151.9 ± 64.1 0.243
HbA1c (%) 8.1 ± 1.5 7.8 ± 1.6 0.100
GA (%) 23.7 ± 4.6 22.0 ± 4.5 p b 0.05
Systolic BP (mm Hg) 126.0 ± 9.6 123.8 ± 8.6 0.280
Diastolic BP (mm Hg) 74.5 ± 9.6 73.2 ± 8.6 0.354
AST (IU/L) 21.8 ± 6.9 22.4 ± 9.7 0.765
ALT (IU/L) 21.5 ± 10.4 21.5 ± 10.0 0.979
BUN (mg/dL) 16.3 ± 4.3 16.7 ± 4.7 0.449
Creatinine (mg/dL) 0.8 ± 0.3 0.9 ± 0.3 p b 0.01
Total cholesterol (mg/dL) 188.1 ± 37.3 185.6 ± 37.8 0.672
Triglycerides (mg/dL) 148.1 ± 93.7 134.3 ± 93.3 0.317
HDL (mg/dL) 54.3 ± 17.0 53.8 ± 16.0 0.858
sRAGE (pg/mL) 935.2 ± 322.4 832.2 ± 350.7 p b 0.05
MCP-1 (pg/mL) 406.3 ± 255.0 356.7 ± 248.2 p b 0.01
UAE (mg/g creatinine) 126.5 ± 248.5 140.0 ± 320.6 0.720
DTSQ
Score 4.4 ± 1.3 4.7 ± 1.1 p b 0.01
Hyperglycemia 3.5 ± 1.6 2.9 ± 1.4 p b 0.05
Hypoglycemia 2.0 ± 1.6 1.6 ± 1.2 p b 0.05
Basal insulin (glargine) (number) 18 18 –
Bolus insulin (U/day) 11.9 ± 9.6 13.1 ± 13.0 0.302
Bolus insulin (aspart/lispro/regular)
(number)
9/13/1 0/0/0 –
Bolus insulin (U/day) 27.0 ± 11.4 27.2 ± 11.4 0.266
Medication
Hypertension (number) 11 11 –
Dyslipidemia (number) 12 12 –
HbA1c; glycated hemoglobin, GA; glycoalbumin, BP; blood pressure, AST; aspartate ami-
notransferase, ALT; alanine aminotransferase, BUN; blood urea nitrogen, HDL-C; high-
density lipoprotein-cholesterol, sRAGE; soluble form of RAGE; MCP-1; monocyte
chemoattractant protein-1, UAE; urinary albumin excretion, DTSQ; diabetes treatment
satisfaction questionnaire.
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viation. Paired t-test was performed for comparisons between base-
line and post-glulisine treatment. Correlations between changes inTable 2
Univariate and multivariate stepwise regression analysis for the determinants of ΔGA and ΔDT
For ΔGA
Univariate Multivariate
Parameters β p β
ΔBody weight (kg) −0.470 p b 0.05
ΔPlasma glucose (mg/dL) 0.681 p b 0.01 0.295
ΔHbA1c (%) 0.786 p b 0.01 0.618
ΔGA (%) – –
ΔSystolic BP (mm Hg) 0.127 0.563
ΔDiastolic BP (mm Hg) 0.213 0.329
ΔAST (IU/L) 0.057 0.796
ΔALT (IU/L) 0.136 0.535
ΔBUN (mg/dL) 0.005 0.981
ΔCreatinine (mg/dL) −0.559 p b 0.01
ΔTotal cholesterol (mg/dL) 0.029 0.896
ΔTriglycerides (mg/dL) 0.466 p b 0.05 0.306
ΔHDL (mg/dL) −0.119 0.590
ΔsRAGE (pg/mL) 0.061 0.782
ΔMCP-1 (pg/mL) 0.066 0.766
ΔUAE (mg/g creatinine) −0.011 0.959
ΔDTSQ score −0.482 p b 0.05
R2 = 0.802 for ΔGA.
R2 = 0.196 for ΔDTSQ score.glycoalbumin (GA), sRAGE, MCP-1, or DTSQ score from baseline
(ΔGA, ΔsRAGE, ΔMCP-1, orΔDTSQ score) and other clinical variables
were determined by a linear regression analysis. To determine indepen-
dent determinants of ΔGA, ΔsRAGE, ΔMCP-1, or ΔDTSQ score, multiple
stepwise linear regression analysis was performed. Intra- and inter-
assay coefﬁcients of variation were 0.7 and 0.7% for HbA1c, 0.9 and
0.7% for GA, 5.7 and 7.7% for sRAGE, 5 and 5.1% for MCP-1, and 0.7 and
2.5% for UAE, respectively [9]. All statistical analyses were performed
with the use of the SPSS system. Statistical signiﬁcance was deﬁned as
p b 0.05.
Demographical data of the subjects are presented in Table 1.
Eighteen patients already received basal glargine therapy. Although
bolus and basal insulin doses were almost unchanged before and
after the glulisine replacement, switching to glulisine for 24 weeks
signiﬁcantly decreased GA, sRAGE, MCP-1 and perceived frequency
of hyperglycemia and hypoglycemia, while it increased DTSQ score
and serum creatinine values (Table 1). As shown in Table 2, multi-
ple stepwise regression analysis showed that Δplasma glucose,
ΔHbA1c and Δtriglycerides were independent determinants of ΔGA
(R2 = 0.802). Furthermore, there was an inverse and independent
correlation of ΔGA with ΔDTSQ (R2 = 0.196) (Table 2). ΔsRAGE
was a sole independent determinant of ΔMCP-1, even after adjustment
for confounders such as age, sex, and change of GA, HbA1c, or plasma
glucose.
We found here that switching from short-acting insulin to glulisine
for 24 weeks signiﬁcantly improved GA in type 2 diabetic patients.More-
over, Δplasma glucose, ΔHbA1c and Δtriglycerides were independently
correlated with ΔGA, and decreased ΔGA was a sole determinant of
the improvement of patient satisfaction evaluated by DTSQ score.
Since GA is a more useful biomarker for postprandial glycemic excur-
sions in type 2 diabetic subjects [11], glulisine might improve GA and
patient satisfaction partly by ameliorating postprandial metabolic de-
rangement due to its rapid absorption with a shorter duration of action
compared with other short-acting insulin such as aspart, lispro, and
regular human insulin [9]. In this study, switching to glulisine also
decreased serum levels of sRAGE and MCP-1. Furthermore, ΔsRAGE
and ΔMCP-1 were independently correlated with each other in step-
wise regression analysis (data not shown). MCP-1, a CC chemokine,
plays an important role in the early phase of atherosclerosis by initiating
monocyte recruitment to the vessel wall, and its expression is elevated
in human atherosclerotic plaques [12]. Given the active involvement ofSQ score.
For ΔDTSQ score
Univariate Multivariate
p β p β p
0.150 0.494
p b 0.05 −0.340 0.112
p b 0.01 −0.421 p b 0.05
−0.482 p b 0.05 −0.482 p b 0.05
−0.124 0.574
0.011 0.959
−0.321 0.136
−0.354 0.098
−0.145 0.508
0.115 0.601
−0.044 0.842
p b 0.01 −0.161 0.464
−0.141 0.522
−0.091 0.679
0.204 0.351
−0.070 0.752
– –
72 J. Ashihara et al. / IJC Metabolic & Endocrine 4 (2014) 70–72RAGE in MCP-1 overexpression and vascular injury in diabetes [13], our
present study suggests that pre-meal injections of bolus insulin glulisine
might be superior to other short-acting insulin in controlling post-
prandial hyperglycemia, improving patient satisfaction, and protecting
against vascular damage in type 2 diabetes partly by suppressing RAGE
activation.
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